S ubstance P (SP)
3 is an 11-aa molecule that binds with high affinity to a neurokinin 1 receptor (NK-1R). NK-1R is expressed on lymphocytes, macrophages, endothelial cells, neurons, and other cell types.
SP and NK-1R can influence immune responses in the liver and intestines as shown in animal models of intestinal infection. For instance, mice pretreated with NK-1R antagonist have a blunted intestinal IFN-␥ response to salmonellosis and are more susceptible to the infection (1) . In murine schistosomiasis, SP through engagement with NK-1R enhances IFN-␥ secretion from Ag-stimulated T cells influencing granuloma formation and IgG2a expression (2, 3) . The NK-1R helps mediate the mucosal injury induced by Clostridium difficile toxin (4) . Also, treatment with blocking SP antiserum (5) or a NK-1R antagonist (6) protects rats from Trichinella spiralis-induced intestinal inflammation.
Using in situ hybridization and immunohistochemistry, it was shown that NK-1R is expressed on normal human intestinal lamina propria (LP) mononuclear cells (LPMC), lymphoid follicles, vascular endothelium, epithelial cells, and myenteric plexus (7, 8) . Isolated human LPMC from healthy regions of colon consistently express NK-1R mRNA and protein, whereas PBMC are negative. Using flow analysis, most (Ͼ60%) of the LPMC NK-1R expression localizes to CD4 ϩ T cells, although other leukocyte subsets express them also (8) . Humans can develop an immunologic disease associated with chronic, destructive inflammation of the intestines. Inflammatory bowel disease (IBD) is usually divided into one of two types called Crohn's disease (CD) or ulcerative colitis. Human IBD probably results from a dysregulated mucosal immune response to normal intestinal bacteria. In human IBD there is increased NK-1R mRNA expression (9) in the tissue. Goode et al. (10) showed, using quantitative PCR, a 7-fold increase in NK-1R transcripts in CD colon and a somewhat more modest increase in ulcerative colitis. Compared with normal control colon, however, immunohistochemistry revealed no ectopic sites of NK-1R expression.
Although resting PBMC may not express NK-1R, studies of NK-1R in human intestine could not discern whether NK-1R expression on human mucosal leukocytes was attributable to infiltration of NK-1R-positive cells or a result of de novo induction. Also, although the intestine is one of the major sites for SP production, the importance of leukocyte NK-1R expression in the mucosa remains unclear. The disproportionate over-representation of NK-1R on human mucosal CD4 ϩ T cells, however, suggests that the expression of NK-1R on T cells is of particular importance.
To help define the importance of NK-1R in human IBD, we examined the effect of NK-1R blockade on the chronic colitis of IL-10 Ϫ/Ϫ mice. It was shown that treatment with a NK-1R antagonist could suppress the ongoing intestinal inflammation. Also revealed was that NK-1R is an inducible mucosal TCR that is regulated by the competing influences of IL-12 and IL-10. The lack of IL-10 in the IL-10 Ϫ/Ϫ mouse may lead to overexpression of NK-1R on T cells, which, in turn, may contribute to the dysregulated mucosal immune response.
Materials and Methods

Mice
This study used wild-type (WT) and IL-10 Ϫ/Ϫ C57BL/6 mice. Breeding colonies for the animals were maintained at the University of Iowa. Some WT mice were infected with the Puerto Rican strain of Schistosoma mansoni by s.c. injection of 50 cercariae as previously described (11) .
Colitis induction and SR 140333 treatment
To induce colitis, mice 4 -5 wk of age were given piroxicam (SigmaAldrich, St. Louis, MO) mixed into their feed (National Institutes of Health-31M) for 2 wk. They received 60 mg of piroxicam/250 g of food wk 1 and 80 mg piroxicam/250 g of food wk 2. Mice subsequently were placed on the normal rodent chow without piroxicam. The colitis was evaluated from 2-16 days after colitis induction.
In some experiments mice received the SP receptor antagonist SR 140333 (Sanofi Recherche, Montpellier, France) at 1 mg/kg/day for 2 wk starting 2 days after discontinuation of the piroxicam. The inhibitor was given by continuous SQ infusion using osmotic pumps (Alzet, Cupertino, CA). Control mice also had implantation of osmotic pumps releasing just control buffer.
Histologic analysis of colitis
Colons (from the ileocecal value to the mid descending colon) were opened longitudinally and rolled up onto a glass rod. The tissue was fixed in 10% neutral buffered formalin, removed from the glass rods without unrolling the tissue, and processed for sectioning. Tissue was sliced to obtain longitudinal sections of colon that were 6 m thick and then stained with H&E for light microscopic examination. The inflammation was scored from 0 -4 using the following criteria: grade 0, no change from normal tissue; grade 1, patchy mononuclear cell infiltrates in the LP; grade 2, more uniform mononuclear cell inflammation involving both the epithelium and LP; this was accompanied by minimal epithelial hyperplasia and slight to no depletion of mucous from goblet cells; grade 3, some epithelial and muscle hypertrophy with patchy lymphocytic infiltrates extending into the muscle layers; there were mucus depletion and occasional crypt abscesses and epithelial erosions; and grade 4, lesions involved most of the intestinal section. The inflammation, which was comprised mostly of lymphocytes and some neutrophils, was transmural and severe. There was prominent thickening of both the epithelial and muscle layers. There was mucus depletion and more frequent crypt abscesses. Ulcerations were frequent.
Cell isolation and T cell enrichment
Single-cell suspensions of splenocytes were prepared from individual mouse spleens by gentle teasing in RPMI. The cells were resuspended briefly in distilled water to lyse RBC. The splenocytes then were washed three times in a large volume of RPMI.
Gut LPMC were isolated as described below. Intestinal tissue was washed extensively with RPMI, and all visible Peyer's patches were removed with a scissors. The intestine was opened longitudinally, cut into 5-mm pieces, and then incubated in 0.5 mM EDTA in calcium-and magnesium-free Hanks' buffer for 20 min at 37°C with shaking to release intraepithelial lymphocytes and epithelial cells. This was repeated after thorough washing. Tissue then was incubated 20 min at 37°C in 20 ml of RPMI containing 10% FCS, 25 mM HEPES buffer, 2 mM L-glutamine, 5 ϫ 10 Ϫ5 M 2-ME, 1 mM sodium pyruvate, 100 U/ml penicillin, 5 mg/ml gentamicin, and 100 mg/ml streptomycin (all from Life Technologies, Gaithersburg, MD) and 1 mg/ml collagenase (Sigma-Aldrich; co130). At the end of the incubation, the tissue was subjected to further mechanical disruption using a 1-ml syringe. To remove debris, the LPMC preparations were washed through a pre-wet gauze layered in a funnel with RPMI. Then, the LPMC were washed once and were sieved through a pre-wet 2-cm nylon wool column gently packed into a 10-ml syringe. After washing, cells (up to 2 ϫ 10 7 ) were layered onto a column of Percoll with a 30/70% gradient. Cells were spun at 2200 ϫ g at room temperature for 20 min. The LPMC collected from the 30/70 interface were washed and maintained on ice until used. Cell viability was 90%, as determined by eosin Y exclusion.
T cells (Thy1.2 ϩ ) were isolated using Ab-coated, paramagnetic beads as described by the manufacturer (Dynal, New Hyde Park, NY). Flow cytometry was used after each separation to assure appropriate recovery and purity (Ͼ98%) of the Thy ϩ T cells. The Thy Ϫ cells contained all the other expected leukocyte subsets and were thoroughly depleted of T cells Ͻ1%.
Cell culture
For cytokine analysis, cells were cultured for 48 h in 96-well microtiter plates (Corning, Cambridge, MA) with 200 l of medium (5 ϫ 10 5 cells/ well) at 37°C. The culture medium was RPMI containing 10% FCS, 25 mM HEPES buffer, 2 mM L-glutamine, 5 ϫ 10 Ϫ5 M 2-ME, 1 mM sodium pyruvate, 100 U/ml penicillin, 5 mg/ml gentamicin, and 100 mg/ml streptomycin (all from Life Technologies). The cells were cultured alone or with anti-CD3 (2C11; American Type Culture Collection, Manassas, VA) and anti-CD28 mAb (BD PharMingen, San Diego, CA; each at 1 g/ml). Isolated T cells were cultured in wells previously coated overnight with anti-CD3 and -CD28 mAb.
Flow cytometric analysis
Spleen or LPMC were washed twice and adjusted to 10 7 cells/ml in FACS buffer (HBSS containing 20 mM HEPES, 10% FCS, and 0.02% sodium azide). The cell suspensions then were dispensed into microcentrifuge tubes, each containing 10 6 cells in 100 l of FACS buffer and stained with saturating amounts of conjugated Abs for 30 min at 4°C. Following staining, cells were washed twice and resuspended for analysis on a FACS 440 flow cytometer (BD Biosciences, Mountain View, CA).
Before adding labeled mAb, each tube received 1 g of 2.4G2 Ab (antiFc␥R) (American Type Culture Collection) to block nonspecific binding of conjugated Abs to FcRs. The other mAbs used for staining were anti-CD4-Cy5 (RM2511; CalTag, Burlingame, CA), anti-CD8a-PE (53-6.7; SigmaAldrich), anti-Thy1.2-FITC (Sigma-Aldrich), and anti-CD19-FITC (1D3; BD PharMingen, San Diego, CA). Also used was [Sar 9 ,Met 11 ]SP (SM-SP) labeled with Alexa Fluor 594 (Molecular Probes, Eugene, OR) in the presence or the absence of NK-1R inhibitor SR 140333 to detect specific binding to NK-1R. Both were used at 10 Ϫ8 M. SM-SP is an analog of SP that only binds the NK-1R receptor. It will not bind with NK-2R or NK-3R. SR 140333 is an extremely selective NK-1R antagonist.
RNA extraction and PCR assay for NK-1R mRNA
For RNA analysis, total cellular RNA was extracted from freshly isolated splenocyte or LP T cell suspensions by homogenization in guanidinium/ acid-phenol. In some experiments isolated splenocytes (4 ϫ 10 7 /flask (T25 flasks; Corning, Cambridge, MA) were cultured at 37°C in 6 ml of RPMI medium for 4 h with or without rIL-12 (1 ng/ml) and/or rIL-10 (1 ng/ml) before RNA extraction. Mucosal T cells (ϳ10 6 /well, 96-well microtiter plates; Corning) were cultured similarly, but for only 40 min. In other experiments splenocytes were incubated with rIL-12 for 8 h. However, rIL-10 was added to some of the cultures 4 h before harvest.
Cellular RNA (5 g) was reverse transcribed with Moloney monkey leukemia virus (400 U) using an 18-mer of oligo(dT) (0.5 g) as primer. The first-strand cDNA was diluted to 250 l, and 15 l (.3 g RNA) was added to PCR buffer containing 2 U Taq DNA polymerase, 1.4 mM Mg Cl 2 , 50 mM KCl, and 100 mM Tris (pH 8.3) in a total volume of 50 l. The sense primer to amplify NK-1R was 5Ј-CCA ACA CCT CCA CCA AGA CTT CTG-3, and the antisense primer was 5Ј-GCC ACA GCT GTC ATG GAG TAG AT-3Ј. The PCR consisted of 40 cycles at 93°C for 1.1 min, 63°C for 1.36 min, and 72°C for 1.14 min. Products of RT-PCR amplification were analyzed by agarose gel electrophoresis using 1.7% sieve GTG agarose (FMC Bioproducts, Rockland, ME) in 0.5ϫ TBE buffer. The authenticity of the 338-bp fragment was confirmed by sequencing.
Total RNA preparations contained equivalent 18-and 28S RNA bands. RNA extracts were quantified spectrophotometrically. Samples were compared for number of hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene transcripts to further confirm equivalent mRNA content and reverse transcription.
NK-1R competitive PCR assay
A plasmid containing an elongated mimic NK-1R sequence of 606 bp was constructed and quantified as previously described (12) . Various quantities of mimic plasmid DNA containing double-stranded elongated NK1 cDNA were added to a series of PCR reactions containing sample cDNA. The concentration of the unknown mRNA was determined through competition with known concentrations of this engineered plasmid by localization of bands of equivalence. The sensitivity of this assay is Ͻ100 NK1 transcripts/g total RNA.
In some experiments a mimic plasmid was used to quantify the HPRT housekeeping mRNA (13) . This was to assure that reactions containing no detectable NK-1R mRNA transcripts had appropriate mRNA content.
The mAbs to IFN-␥ (HB170), IL-4, and IL-5 were from cell lines maintained in our laboratory. These mAbs were purified from culture supernatants by ammonium sulfate precipitation.
Statistical analysis
Data are the mean Ϯ SE of multiple determinations. Difference between two groups was compared using Student's t test. A value of p Ͻ 0.05 was considered significant.
Results
LP T cells express NK-1R mRNA in piroxicam-induced colitis
NK-1R is an inducible TCR. SP is a Th1-type cytokine that can regulate T cell IFN-␥ production through engagement of this receptor. It first was determined whether T cells in the LP of IL-10 Ϫ/Ϫ or WT mice without colitis expressed NK-1R mRNA. T cell RNA from dispersed LPMC isolated from the terminal ileum of 7-to 8-wk-old IL-10 Ϫ/Ϫ or WT mice raised in a specific pathogenfree facility expressed no NK-1R transcripts. NK-1R transcripts were measured using an NK-1R quantitative PCR assay sensitive down to 100 transcripts/g RNA (Fig. 1) .
Four-to 5-wk-old IL-10 Ϫ/Ϫ mice then were given piroxicam for 2 wk to induce colitis. After induction, LP T cells were isolated from the mucosa. These cells expressed NK-1R mRNA strongly (Fig. 2) . The level of expression was 45,036 Ϯ 1,158 transcripts/g RNA (ϮSE; n ϭ 4). LP T cells from age-matched IL-10 Ϫ/Ϫ controls that received no piroxicam had little or no NK-1R transcripts. Piroxicam-treated, WT animals had no colitis, and their LP T cells did not express NK-1R mRNA (data not shown).
In the IL-10 Ϫ/Ϫ mice with colitis, flow analysis using Alexa-SM-SP showed that ϳ17% of LP CD4 ϩ T cells bound SP. Alexa-SM-SP was displaced by the NK-1R inhibitor SR 140333 showing that the binding was specific (Fig. 3) . Mucosal NK-1R ϩ CD4 ϩ T cells were CD25 Ϫ , and ϳ90% of these cells were CD45RB low . A small subset of CD8 ϩ cells was positive also (data not shown). No specific binding was seen on T cells from IL-10 Ϫ/Ϫ mice without colitis.
IL-10 inhibits NK-1R expression
IL-10 is an important regulator of T cell function. Splenic T cells from young and healthy wild-type mice maintained specific pathogen free do not respond to IL-12 with NK-1R induction. However, IL-12 readily induces NK-1R expression on splenic CD4 ϩ T cells in murine schistosomiasis. Thus, experiments determined whether IL-10 regulates IL-12-dependent, NK-1R mRNA induction using splenocytes from schistosome-infected animals. Splenic CD4 ϩ T cells were exposed to rIL-12 in the presence or the absence of rIL-10. Fig. 4A shows that IL-12 induced nearly 50 ϫ 10 3 NK-1R transcripts/g splenic T cell RNA after just a 4-h exposure. IL-10 totally prevented this expression (Ͻ100 transcripts/g of total RNA). IL-12-induced, T cell NK-1R expression persisted for at least 48 h in vitro. In other experiments cells were exposed to IL-10 only after IL-12 induced NK-1R transcripts. IL-10 reversed NK-1R mRNA expression by ϳ80% after just a 4-h exposure (Fig.  4B ). IL-10 suppressed NK-1R mRNA expression with comparable efficiency even after T cells were maintained in culture for 24 h (data not shown).
IL-12 induces and IL-10 regulates NK-1R expression in mucosal T cells
LP T cells were isolated from 4-to 5-wk-old, colitis-free, IL-10
Ϫ/Ϫ mice. These cells were cultured for 40 min in the presence or the absence of IL-12. Some cultures contained IL-10 also. Fig.  5 shows that IL-12 induces NK-1R transcripts in resting mucosal T cells, and that IL-10 prevents this induction. Similar experiments using LP T cells from 4-to 5-wk-old WT control animals yielded similar results (data not shown).
NK-1R blockade reverses mucosal inflammation
Mice received piroxicam to induce colitis. Previous studies showed that this induces severe colitis that persists at least 4 wk after stopping piroxicam. After induction of the inflammation, the animals were treated with the NK-1R antagonist SR140333 for 2 wk or an appropriate control. The colons then were examined for colitis. Control mice had severe colitis with ulcerations, muscle thickening, and epithelial hypertrophy. Mice treated with NK-1R antagonist had only mild inflammation, limited to the LP. There was no muscle or epithelial hypertrophy (Fig. 6) . However, T cells from the LP of these treated mice continued to express NK-1R transcripts (data not shown).
Also examined was LPMC cytokine secretion from the SR 140333-treated and control colitic mice. Isolated LPMC from either the control or NK-1R antagonist treatment groups were composed of ϳ40% T cells, 40% B cells, and 20% macrophage as determined by flow analysis. Isolated LPMC from control mice cultured in vitro released IFN-␥ (Fig. 7) . The LP T cells isolated using paramagnetic beads produced IFN-␥, whereas LPMC devoid of T cells made none. LPMC isolated from mice receiving SR 140333 made no IFN-␥ even after anti-CD3 and anti-CD28 stimulation. There was no IL-4 or IL-5 detected in the culture supernatants from either group. 
Discussion
This study examined the expression and regulation of T cell NK-1R in the intestinal mucosa. Also explored was the role of this receptor and, by inference, SP in the regulation of a Th1-type chronic colitis.
We addressed these questions using an animal model of IBD that is most suggestive of human CD. The model chosen was piroxicam-induced, IL-10 Ϫ/Ϫ colitis (14) . IL-10 Ϫ/Ϫ mice develop chronic colitis that gradually worsens as the animals age. However, young animals rapidly develop severe inflammation of the colon and terminal ileum when they are given a nonsteroidal antiinflammatory medication (piroxicam). The colitis persists following withdrawal of the medication. Arachidonic acid blockade by piroxicam triggers a lymphocyte-rich, intestinal Th1-type inflammation that generates IFN-␥ and IL-12. There is little or no IL-4 or IL-5 produced. As postulated for human IBD, IL-10 Ϫ/Ϫ colitis results from a dysregulated immune response to constituents of normal intestinal flora (15) .
This study showed that mucosal LP T cells from young IL-10 Ϫ/Ϫ mice raised in an exceedingly clean, specific pathogen-free facility do not express NK-1R transcripts. However, mucosal T cells strongly express NK-1R mRNA and NK-1R protein after induction of colitis. WT, age-matched, specific pathogen-free mice do not develop colonic inflammation following identical piroxicam administration, and their mucosal T cells do not express NK-1R transcripts.
We used Alexa-labeled SM-SP at 10 Ϫ8 M and flow analysis to estimate the number of T cells expressing NK-1R protein. This was an extremely sensitive and highly specific method for demonstrating NK-1R on mucosal T cells. SM-SP is a highly selective ligand of NK-1R. It does not bind the other tackykinin receptors, NK-2 or NK-3. Also, the NK-1R-selective inhibitor SR 140333 displaced the binding, which further suggests that this assay was NK-1 receptor specific. Approximately 17% of the CD4 ϩ T cells displayed NK-1R after the onset of colitis. Mucosal NK-1R ϩ
CD4
ϩ T cells were CD25 Ϫ , and 90% of these cells were CD45RB low . Thus, they expressed the activation/memory phenotype. Our analysis could have underestimated NK-1R expression, since the gut is an environment rich in SP, and surface NK-1R internalizes once engaged with its ligand (16, 17) .
NK-1R is an inducible receptor on CD4 ϩ splenic and liver granuloma T cells in murine schistosomiasis (12) . TCR activation by Ag or IL-12 stimulates its expression. The experiments presented here revealed that IL-12 can induce NK-1R expression in resident LP T cells isolated from the mucosal of young IL-10 Ϫ/Ϫ mice before the onset of their colitis.
IL-12 has an important physiologic role in IL-10 Ϫ/Ϫ colitis. The intestinal inflammation generates IL-12. Also, blocking IL-12 can delay the onset of disease and even partially reverse the ongoing inflammation (18) . Thus, it is reasonable to conclude that NK-1R on LP T cells is inducible through the action of endogenously produced IL-12.
IL-10 is critically important for limiting immunoreactivity in the intestines. This was shown using both the IL-10 Ϫ/Ϫ mouse that develops spontaneous colitis (19) and the SCID T cell transfer model of IBD (20) . IL-10 from T cells is particularly important. IL-10 inhibits both macrophage and dendritic cell function. It also promotes T cell tolerance by blocking the CD28 costimulatory pathway. Regulatory T cells may function partly through the production of 22) . However, it remains uncertain how it controls intestinal inflammation.
A major new observation of this investigation was that IL-10 can prevent IL-12-mediated, NK-1R induction in splenic and LP T cells. Also, it can suppress ongoing NK-1R expression. Several animal models support a physiological role for SP and its receptor in liver and intestinal inflammation (1) (2) (3) (4) (5) (6) . In many cases NK-1R functions as an enhancer of Th1 pathways. It can stimulate IL-12 (23) and IFN-␥ production (24) and inhibit TGF-␤ synthesis (25) . It is tempting to speculate that IL-10 helps limit Th1 reactivity in the intestine through the control of mucosal T cell NK-1R expression.
The capacity of SP to function as an inflammatory mediator is governed at several levels. As shown in this report, one point of control is through transcriptional regulation of the biosynthesis of its natural ligand NK-1R (12, 26) . Also, engagement of SP with its receptor at the cell surface results in temporary receptor desensitization and loss of bioavailability. This results from transient disruption in receptor signal transduction, and internalization of the receptor (16, 17) .
Neutral endopeptidase (NEP) is an enzyme expressed on the surface of many cells that degrades SP. The bioactivity of SP in extracellular fluid is regulated partly through the local expression of this enzyme. Inhibition or loss of NEP makes mice more susceptible to intestinal inflammation (27, 28) . NEP Ϫ/Ϫ mice are more sensitive to dinitrobenzene sulfonic acid-induced colitis. Pharmacological blockade of NK-1R prevents this heightened inflammation (27) . These models suggest that NEP, perhaps through the failure to degrade SP, also helps govern mucosal immune responses.
Our experiments using IL-10 Ϫ/Ϫ mice showed that a NK-1R antagonist used in vivo can suppress ongoing colitis and intestinal IFN-␥ production. Di Sebastiano et al. (29) reported that the same NK-1R inhibitor helped prevent inflammation in rat trinitrobenzene-induced colitis. Thus, these models of intestinal inflammation collectively support the concept that SP, the major endogenous ligand for NK-1R, has an important role in intestinal inflammation.
The point of action of the inhibitor was not determined in this current investigation. NK-1R are on vascular endothelial cells (30) , epithelial cells (31) , smooth muscle cells, neurons, lymphocytes (32, 33) , macrophages (23, 34) , dendritic cells, and other cell types. The vascular NK-1R can promote egress of leukocytes from blood vessels. Macrophage NK-1R activation can stimulate IL-12 (23) and reduce TGF-␤ secretion (25) . The T cell NK-1R enhances IFN-␥ production (24) . The colitis of IL-10 Ϫ/Ϫ mice is dependent on IL-12 and IFN-␥, since blockade of IL-12 and, to a lesser extent, IFN-␥ reduces the intensity of the ongoing inflammation (18) . It is most likely that the NK-1R antagonist affected the colitis through disruption of several of these important immunoregulatory pathways.
SP belongs to the tachykinin family of hormones. It derives from a precursor protein called preprotachykinin A, which is encoded by the tachykinin 1 gene. Preprotachykinin A also can be processed to produce neurokinin A and two N-terminal elongated forms of neurokinin A, called neuropeptide K and neuropeptide ␥. Another tachykinin, neurokinin B, comes from preprotachykinin B, which is encoded by a different gene (murine tachykinin 2 or human tachykinin 3). Yet another tachykinin gene, tachykinin 4, produces preprotachykinin c and a novel tachykinin called hemokinin (35) .
Three distinct tachykinin receptors, designated NK-1, NK-2,and NK-3, mediate the biological function of tachykinins. SP and hemokinin bind NK-1R with high affinity (36) . However, hemokinin may signal somewhat differently from SP and may have some separate functions (35) . Most reports suggest that the other tachykinins bind either NK-2R or NK-3R with high affinity and are low affinity agonists of NK-1R.
The expression of NK-1R on intestinal leukocytes could imply an important role for SP in the regulation of mucosal inflammation. While SP is abundant in the intestines, there are somewhat conflicting data regarding the concentration of SP in the intestinal mucosa of patients with IBD (37) (38) (39) . Some studies report high levels that correlate with the activity of the disease (38 -40) . Others also report high levels of SP in intestinal nerve fibers (41) (42) (43) . It currently is unknown whether the other natural agonist of NK-1R, hemokinin, is expressed in the gut.
In summary, these are the first data showing that NK-1R is important for the ongoing intestinal immune response in a spontaneous murine model of IBD. Also revealed was the importance of IL-12 and IL-10 for the control of mucosal T cell NK-1R expression. This may be physiologically important, since NK-1R is heavily expressed on mucosal T cells in human IBD (10) . The piroxicam-IL-10 model of IBD will allow further exploration into the roles of tachykinins and their receptors in the control of intestinal inflammation.
